Abstract 17398: Suppression-Replacement Gene Therapy for LMNA -Mediated Cardiomyopathies
Abstract
Background: LMNA encodes for nuclear lamina proteins lamin A and C, which are critical for nuclear architecture maintenance, chromatin organization, and gene expression. Pathogenic variants in LMNA are associated with a range of pathologies in tissues, including the heart. Cardiac laminopathies manifest as structural changes and arrhythmias, which can lead to end-stage heart failure and sudden cardiac death. Current therapies for arrhythmogenic cardiomyopathies (ACM) fail to target the underlying molecular cause of the disease. Purpose: To test the efficacy of a novel LMNA suppression-replacement (SupRep) gene therapy in an Lmna H222P/H222P mouse model of LMNA-ACM. Methods: A POLARIS-101 TM (AAV-SLB101)LMNA-SupRep gene therapy was created by combining two components into a single construct expressed using a single ubiquitous promoter: a custom-designed LMNA miRNA-based suppression sequence and a miRNA-immune (miMM) LMNA cDNA replacement sequence designed to create both lamin A and lamin C isoforms. CRISPR-Cas9 was used to insert Lmna H222P variant in C57BL/6 mice. Lmna H222P/H222P mice received a single retro-orbital injection of the LMNA-SupRep therapy at 1 month of age. Systolic cardiac function of animals was assessed by transthoracic echocardiography using Vevo F2 ultrasound imaging system. Degree of skeletal myopathy was determined through development of kyphosis and limb paralysis. Lifespan was recorded. Results: The lead LMNA -targeting miRNA suppressed LMNA expression by 88% in HEK-TSA201 cell system . Lmna H222P/H222P mice developed dilatation of the left ventricle (LV), LV wall thinning, with reduced systolic function, and enlarged atria compared to littermate wild type mice. Following the treatment, ejection fraction was preserved in 5 month old SupRep-treated males compared to vehicle-treated littermate controls (PBS: 43.47%±7.25%, n=10 vs SupRep: 53.24%±5.08%, n=13) and 6.5 month old SupRep-treated females compared to the vehicle-treated littermate controls (PBS: 38.66%±15.04%, n=8 vs SupRep: 58.33%±8.10%, n=10). Median survival in vehicle treated male mice was 197 days, while 69% of SupRep-treated males were alive at 270 days when study was terminated. Median survival in vehicle treated female mice was 235 days, while 92% of SupRep-treated females were alive at 300 days when study was terminated. Conclusion: We demonstrate the first pre-clinical in vivo proof-of-concept SupRep gene therapy for the correction of LMNA -mediated ACM and skeletal myopathy. LMNA -SupRep gene therapy restored the structural and functional cardiac and skeletal muscle abnormalities observed in a LMNA-ACM mouse model and significantly extended the lifespan of the animals.